---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-23-052715"
form_type: "8-K"
ticker: "GYRE"
cik: "0001124105"
company_name: "GYRE THERAPEUTICS, INC."
filed_at: "2023-11-13T23:59:59+00:00"
generated_at: "2026-06-08T04:37:26.726126+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Gyre Therapeutics presents Hydronidone preclinical data at AASLD; plans US clinical program in 2024

## Summary
- Poster at AASLD Liver Meeting (Nov 10-14, 2023) shows Hydronidone reduces liver fibrosis in mouse models.
- Hydronidone inhibits hepatic stellate cell activation via Smad7-mediated TGF-β degradation.
- Company expects to initiate U.S. clinical program for MASH-associated fibrosis in 2024.
- Specific Smad7 knockdown in vivo blocked Hydronidone's antifibrotic effect, confirming mechanism.

## SEC filing metadata
- accession: 0001140361-23-052715
- form_type: 8-K
- ticker: GYRE
- cik: 0001124105
- company_name: GYRE THERAPEUTICS, INC.
- filed_at: 2023-11-13T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1124105/000114036123052715/0001140361-23-052715-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1124105/000114036123052715/ny20009756x16_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-23-052715
- JSON: https://secwatch.observer/filing/0001140361-23-052715.json
- Plain text: https://secwatch.observer/filing/0001140361-23-052715.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.